icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
dLxEnmSD8NYyDfFM